5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow LY686017: new trials by email Literature Review of LY686017 trials Research Report on LY686017
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis VLY-686 (Tradipitant), Placebo - Gastroparesis | Phase 2 | Completed | Vanda Pharmaceuticals | 152 | 2016-11-01 | 2024-08-06 |
| Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis VLY-686, Placebo - Treatment-resistant Pruritus Associated With Atopic Dermatitis | Phase 2 | Completed | Vanda Pharmaceuticals | 69 | 2013-12-10 | 2024-06-11 |
| A Study in the Treatment of Alcohol Dependence. LY686017, Placebo - Alcohol Dependence | Phase 2 | Completed | Eli Lilly and Company | 190 | 2008-12-01 | 2019-09-17 |
| Effect of LY686017 on Alcohol Craving LY686017, Placebo - Alcohol Dependence, Alcoholism | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 66 | 2006-03-01 | 2010-04-20 |
| Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder LY686017, paroxetine, placebo - Social Phobia | Phase 2 | Completed | Eli Lilly and Company | 185 | 2004-12-01 | 2007-02-13 |
Alcoholism (2) · Anxiety Disorders (1) · Dermatitis, Atopic (1) · Gastroparesis (1) · Phobia, Social (1) · Pruritus (1)
Eli Lilly and Company (2) · Vanda Pharmaceuticals (2) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1)
United States (4) · Germany (1)